Jazz Pharmaceuticals Plc (JAZZ) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Jazz Pharmaceuticals Plc  (NASDAQ: JAZZ)
 

Jazz Pharmaceuticals Plc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

JAZZ Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 10.38 % 14.14 % 10.2 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 2.87 % -1.07 % -2.54 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 13.48 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 2.54 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 12.54 % 7.52 % 8.67 % 13.63 %


JAZZ's Growth Comparisons in III. Quarter 2026




Jazz Pharmaceuticals Plc's 10.38% year on year Revenue increase in the third quarter 2026 to 1.24 billions, marks slow-down from Jazz Pharmaceuticals Plc's growth trends, and competes unfavorably to the 14.14% rise in the Major Pharmaceutical Preparations industry, but beating the 10.2% improvement in the Healthcare sector. Comparing the third quarter sales, Jazz Pharmaceuticals Plc was trailing overall market not just the Major Pharmaceutical Preparations industry.

Comparing the company's Revenue to the second quarter results, sales were higher by 2.87% . On the yearly basis, average annual sales growth for Jazz Pharmaceuticals Plc is 12.54%, while S & P 500's including only Businesses with the third quarter 2026 earnings, average annual sales growth is 13.63% over the past five years.

JAZZ Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product and Services, Product Sales Net of Deductions
-
54.85 %
Product and Services, Royalties and Contract Revenue
-
48.54 %
Xywav
215.76 %
54.9 %
Xyrem
160.49 %
50.57 %
Sleep
-
54.62 %
Epidiolex/Epidyolex
-
54.51 %
Epilepsy
-
54.51 %
Zepzelca
292.46 %
50.48 %
Rylaze/Enrylaze
-
52.31 %
Defitelio/defibrotide
-
55.48 %
Modeyso
1266.03 %
68.19 %
Vyxeos
144.79 %
58.62 %
Ziihera
493.55 %
71.78 %
Oncology
-
55.64 %
Other
25.99 %
0 %
High Sodium AG Oxybate Product Royalty Revenue
-
48.92 %
Other royalty and contract revenues
190.29 %
-
United States
207.35 %
53.92 %
Europe
230.42 %
50.42 %
Other Countries
-
97.79 %
Total
10.38 %
2.87 %


Growth Rates of JAZZ's Income in the third quarter 2026


JAZZ Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) - -23.95 % -12.31 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) - 30.85 % 31.01 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) -52.51 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change - 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -16.85 % -38.84 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - -26.31 % -63.29 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - 6.33 % 9.9 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -78.11 % -9.97 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - 14.58 % 8.91 % -28.64 %

JAZZ Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - -17.47 % -39.18 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) - 21.94 % 11.48 % 27.07 %
Y / Y Net Income Change (Q3 TTM) - 5.05 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) -78.11 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth - 14.16 % 9.09 % 23.95 %

JAZZ's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -31.09 % -38.84 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - -35.27 % -63.29 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -76.15 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -0.46 % 8.91 % -28.64 %



JAZZ EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - -31.6 % -39.18 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) - 7.1 % 11.48 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -79.02 % 0.05 % 10.56 % 4.93 %
EPS Net 5 Year Avg. Change - 14.16 % 9.09 % 23.95 %



Jazz Pharmaceuticals Plc reported bottom-line of $ -7.48 in the third quarter, compare to $ 4.08 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -31.6%, while Healthcare sector decreased by -39.18%, and overall market improved by 90.69%.

Comparing company's EPS to the second quarter results, income per share were higher by 2.87% . On the yearly basis, average annual income per share growth for Jazz Pharmaceuticals Plc is 12.54%, while S & P 500's including only the businesses with the third quarter 2026 Results, average annual income per share growth is 23.95% over the past five years.

JAZZ Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 14.08 % 26.04 % 44.7 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 23.21 % -29.98 % -42.72 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) 16.35 % 12.35 % 19.45 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 4.23 % 3.58 % 5.9 % 15.75 %
Free Cash Flow 5 Year Avg. Change 9.13 % 0.88 % 0.41 % 1.79 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -64.14 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) -10.5 % -21.14 % -19.33 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) 82.6 % 15.45 % 8.85 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -12.58 % 1.84 % 0.98 % 23.05 %
Capital Expenditures 5 Year Avg. Change 5.49 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.